Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: A review of the scientific evidence

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 1, 2008, Pages 45-55

  Karageorgopoulos, Drosos E ^a   Kelesidis, Theodore ^a,b   Kelesidis, Iosif ^a,c   Falagas, Matthew E ^a,b,d  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d HENRY DUNANT HOSPITAL   (Greece)

Author keywords

Acinetobacter baumannii; Bloodstream infections; Glycylcyclines; Imipenem; Microbial drug resistance

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; AZTREONAM; CARBAPENEM; CEFEPIME; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DOXYCYCLINE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; POLYMYXIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULBACTAM; SULTAMICILLIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTEREMIA; BACTERIAL INFECTION; BACTERIUM ISOLATE; BROTH DILUTION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; DRUG RESPONSE; HUMAN; INFORMATION RETRIEVAL; MEDLINE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; REPEATED DRUG DOSE; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; REVIEW; STEADY STATE; SYSTEMATIC REVIEW; VENTILATOR ASSOCIATED PNEUMONIA;

ACINETOBACTER; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE;

EID: 45749108249     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn165     Document Type: Review

References (96)

1. Van Looveren M, Goossens H. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004; 10: 684-704.
2. Houang ET, Chu YW, Leung CM et al. Epidemiology and infection control implications of Acinetobacter spp. in Hong Kong. J Clin Microbiol 2001; 39:228-34.
3. Seifert H, Baginski R, Schulze A et al. The distribution of Acinetobacter species in clinical culture materials. Zentralbl Bakteriol 1993; 279: 544-52.
4. Tjernberg I, Ursing J. Clinical strains of Acinetobacter classified by DNA-DNA hybridization. APMIS 1989; 97: 595-605.
5. Cisneros JM, Reyes MJ, Pachon J et al. Bacteremia due to Acinetobacter baumannii: Epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996; 22: 1026-32.
6. Humphreys H, Towner KJ. Impact of Acinetobacter spp. in intensive care units in Great Britain and Ireland. J Hosp Infect 1997; 37 281-6.
7. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: Microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996; 9: 148-65.
8. Falagas ME, Karveli EA, Siempos II et al. Acinetobacter infections: A growing threat for critically ill patients. Epidemiol Infect 2007;1-11.
9. Falagas ME, Mourtzoukou EG, Polemis M et al. Trends in antimicrobial resistance of Acinetobacter baumannii clinical isolates from hospitalised patients in Greece and treatment implications. Clin Microbiol Infect 2007; 13: 816-9.
10. Falagas ME, Karveli EA. The changing global epidemiology of Acinetobacter baumannii infections: A development with major public health implications. Clin Microbiol Infect 2007; 13: 117-9.
11. Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977-2000. Infect Control Hosp Epidemiol 2003; 24: 284-95.
12. Gamacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003; 31: 2742-51.
13. Fagon JY, Chastre J, Hance AJ et al. Nosocomial pneumonia in ventilated patients: A cohort study evaluating attributable mortality and hospital stay. Am J Med 1993; 94: 281-8.
14. Falagas ME, Rafailidis PI. Attributable mortality of Acinetobacter baumannii: No longer a controversial issue. Crit Care 2007; 11: 134.
15. Falagas ME, Kasiakou SK, Rafailidis PI et al. Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother 2006; 57: 1251-4.
16. Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: A systematic review of matched cohort and case-control studies. Crit Care 2006; 10: R48.
17. Aronson NE, Sanders JW, Moran KA. In harm's way: Infections in deployed American military forces. Clin Infect Dis 2006; 43: 1045-51.
18. Ferrara AM. Potentially multidrug-resistant non-fermentative Gram-negative pathogens causing nosocomial pneumonia. Int J Antimicrob Agents 2006; 27: 183-95.
19. Levin AS. Treatment of Acinetobacter spp. infections. Expert Opin Pharmacother 2003; 4: 1289-96.
20. Rafailidis PI, Ioannidou EN, Falagas ME. Ampicillin/sulbactam: Current status in severe bacterial infections. Drugs 2007; 67: 1829-49.
21. Bou G, Cervero G, Dominguez MA et al. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: High-level carbapenem resistance in A. baumannii is not due solely to the presence of β-lactamases. J Clin Microbiol 2000; 38: 3299-305.
22. Falagas ME, Kasiakou SK. Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333-41.
23. Quale J, Bratu S, Landman D et al. Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. Clin Infect Dis 2003; 37: 214-20.
24. Rice LB. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43 Suppl 2: S100-5.
25. Ruiz J, Nunez ML, Perez J et al. Evolution of resistance among clinical isolates of Acinetobacter over a 6-year period. Eur J Clin Microbiol Infect Dis 1999; 18: 292-5.
26. Falagas ME, Bliziotis IA. Pandrug-resistant Gram-negative bacteria: The dawn of the post-antibiotic era? Int J Antimicrob Agents 2007; 29: 630-6.
27. Falagas ME, Bliziotis IA, Kasiakou SK et al. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis 2005; 5: 24.
28. Falagas ME, Kasiakou SK, Tsiodras S et al. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: A review of the recent literature. Clin Med Res 2006; 4: 138-46.
29. Li J, Rayner CR, Nation RL et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumanii. Antimicrob Agents Chemother 2006; 50: 2946-50.
30. Matthaiou DK, Michalopoulos A, Rafailidis PI et al. Risk factors associated with the isolation of colistin-resistant Gram negative bacteria: A matched case-control study. Crit Care Med 2008; 36 807-11.
31. Garrison MW, Neumiller JJ, Setter SM. Tigecycline: An investigational glycylcycline antimicrobial with activity against resistant Gram-positive organisms. Clin Ther 2005; 27: 12-22.
32. Petersen PJ, Jacobus NV, Weiss WJ et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43: 738-44.
33. Bauer G, Berens C, Projan SJ et al. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother 2004; 53: 592-9.
34. Zhanel GG, Homenuik K, Nichol K et al. The glycylcyclines: A comparative review with the tetracyclines. Drugs 2004; 64: 63-88.
35. Chopra I, Roberts M. Tetracycline antibiotics: Mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001; 65: 232-60.
36. Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000; 36: 19-36.
37. Hoellman DB, Pankuch GA, Jacobs MR et al. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 2000; 44: 1085-8.
38. Jacobus NV, McDermott LA, Ruthazer R et al. In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob Agents Chemother 2004; 48: 1034-6.
39. Lortholary O, Fagon JY, Hoi AB et al. Nosocomial acquisition of multiresistant Acinetobacter baumannii. risk factors and prognosis. Clin Infect Dis 1995; 20: 790-6.
40. Murphy TM, Deitz JM, Petersen PJ et al. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob Agents Chemother 2000; 44: 3022-7.
41. Pankey GA. Tigecycline. J Antimicrob Chemother 2005; 56: 470-80.
42. Sader HS, Jones RN, Stilwell MG et al. Tigecycline activity tested against 26,474 bloodstream infection isolates: A collection from 6 continents. Diagn Microbiol Infect Dis 2005; 52: 181-6.
43. Tigecycline Evaluation and Surveillance Trial (TEST). http://www.testsurveillance.com (12 December 2007, date last accessed).
44. Betriu C, Rodriguez-Avial I, Gomez M et al. Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study. Diagn Microbiol Infect Dis 2006; 56 437-44.
45. Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005; 41 Suppl 5: S315-32.
46. Petersen PJ, Bradford PA, Weiss WJ et al. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens. Antimicrob Agents Chemother 2002; 46: 2595-601.
47. Fritsche TR, Sader HS, Stilwell MG et al. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections 2000-04. Diagn Microbiol Infect Dis 2005; 52: 195-201.
48. Sader HS, Jones RN, Dowzicky MJ et al. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005; 52: 203-8.
49. Petersen PJ, Labthavikul P, Jones CH et al. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother 2006; 57: 573-6.
50. Hoban DJ, Bouchillon SK, Johnson BM et al. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005; 52: 215-27.
51. Zhang YY, Zhou L, Zhu DM et al. In vitro activities of tigecycline against clinical isolates from Shanghai, China. Diagn Microbiol Infect Dis 2004; 50: 267-81.
52. Draghi DC, Tench S, Dowzicky MJ et al. Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance. Chemotherapy 2008; 54: 91-100.
53. Mezzatesta ML, Trovato G, Gona F et al. In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy. Ann Clin Microbiol Antimicrob 2008; 7: 4.
54. Ratnam I, Franklin C, Spelman DW. In vitro activities of 'new' and 'conventional' antibiotics against multi-drug resistant Gram negative bacteria from patients in the intensive care unit. Pathology 2007; 39: 586-8.
55. Insa R, Cercenado E, Goyanes MJ et al. In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. J Antimicrob Chemother 2007; 59: 583-5.
56. Tan TY, Ng LS. Susceptibility of multi-resistant Gram-negative bacilli in Singapore to tigecycline as tested by agar dilution. Ann Acad Med Singapore 2007; 36: 807-10.
57. Iredell J, Thomas L, Power D et al. Tigecycline resistance in Australian antibiotic-resistant Gram-negative bacteria. J Antimicrob Chemother 2007; 59: 816-8.
58. Hoban DJ, Bouchillon SK, Dowzicky MJ. Antimicrobial susceptibility of extended-spectrum beta-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcy-cline antimicrobial. Diagn Microbiol Infect Dis 2007; 57: 423-8.
59. Curcio D, Fernandez F. Acinetobacter spp. susceptibility to tigecycline: A worldwide perspective. J Antimicrob Chemother 2007; 60: 449-50.
60. Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007; 59: 772-4.
61. Scheetz MH, Qi C, Warren JR et al. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51: 1621-6.
62. Thamlikitkul V, Tiengrim S, Tribuddharat C. Comment on: High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007; 60: 177-8.
63. Tiengrim S, Tribuddharat C, Thamlikitkul V. In vitro activity of tigecycline against clinical isolates of multidrug-resistant Acinetobacter baumannii in Siriraj Hospital, Thailand. J Med Assoc Thai 2006; 89 Suppl 5: S102-5.
64. Song JY, Kee SY, Hwang IS et al. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007; 60: 317-22.
65. Akcam FZ, Kaya O, Basoglu N et al. E-test minimum inhibitory concentrations for tigecycline against nosocomial Acinetobacter baumannii strains. J Chemother 2007; 19: 230-1.
66. Halstead DC, Abid J, Dowzicky MJ. Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial. J Infect 2007; 55: 49-57.
67. Sands M, McCarter Y, Sanchez W. Synergy testing of multidrug resistant Acinetobacter baumanii against tigecycline and polymyxin using an E-test methodology. Eur J Clin Microbiol Infect Dis 2007; 26 521-2.
68. Seifert H, Stefanik D, Wisplinghoff H. Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates. J Antimicrob Chemother 2006; 58: 1099-100.
69. Bogaerts P, Naas T, Wybo I et al. Outbreak of infection by carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-58 in Belgium. J Clin Microbiol 2006; 44: 4189-92.
70. Vahaboglu H, Budak F, Kasap M et al. High prevalence of OXA-51-type class D β-lactamases among ceftazidime-resistant clinical isolates of Acinetobacter spp.: Co-existence with OXA-58 in multiple centres. J Antimicrob Chemother 2006; 58: 537-42.
71. Souli M, Kontopidou FV, Koratzanis E et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, Gram-negative and Gram-positive clinical isolates from Greek hospitals. Antimicrob Agents Chemother 2006; 50: 3166-9.
72. Lolans K, Rice TW, Munoz-Price LS et al. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother 2006; 50 2941-5.
73. Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C et al. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004; 48: 4479-81.
74. Henwood CJ, Gatward T, Warner M et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002; 49: 479-87.
75. EUCAST technical note on tigecycline. Clin Microbiol Infect 2006; 12: 1147-9.
76. BSAC Methods for Antimicrobial Susceptibility Testing Version 6.1. http://www.bsac.org/_db/_documents/version_6.1.pdf (10 November 2007, date last accessed).
77. Hope R, Parsons T, Mushtaq S et al. Determination of disc breakpoints and evaluation of Etests for tigecycline susceptibility testing by the BSAC method. J Antimicrob Chemother 2007; 60: 770-4.
78. Wyeth Pharmaceuticals Inc., Collegeville, PA. Tygacil™ package insert, 2005. http://www.fda.gov/cder/foi/label/2005/021821lbl.pdf (12 December 2007, date last accessed).
79. Anthony KB, Fishman NO, Linkin DR et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. Clin Infect Dis 2008; 46: 567-70.
80. Schafer JJ, Mangino JE. Multidrug-resistant Acinetobacter baumannii Osteomyelitis from Iraq. Emerg infect Dis 2008; 14: 512-4.
81. Wadi JA, Al Rub MA. Multidrug resistant Acinetobacter nosocomial meningitis treated successfully with parenteral tigecycline. Ann Saudi Med 2007; 27: 456-8.
82. Schafer JJ, Goff DA, Stevenson KB et al. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 2007; 27: 980-7.
83. Curcio D, Fernandez F, Duret F. Tigecycline use in critically ill older patients: Case reports and critical analysis. J Am Geriatr Soc 2007; 55: 312-3.
84. Reid GE, Grim SA, Aldeza CA et al. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 2007; 27: 1198-201.
85. Leclerc T, Perez JP, Debien B et al. Treatment of a septic shock due to multiresistant Acinetobacter baumannii with tigecycline in combination. Ann Fr Anesth Reanim 2007; 26: 1056-8.
86. Taccone FS, Rodriguez-Villalobos H, De Backer D et al. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur J Clin Microbiol Infect Dis 2006; 25: 257-60.
87. Wickens H, Warr C, Jepson A et al. An outbreak of multi-drug resistant Acinetobacter baumannii infection on an intensive care unit (ICU), and treatment with tigecycline. In: Program and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 17-20 September 2006. Abstract K-1498, p. 355. American Society for Microbiology, Washington, DC, USA.
88. Peleg AY, Potoski BA, Rea R et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: A cautionary report. J Antimicrob Chemother 2007; 59: 128-31.
89. Gales AC, Jones RN, Sader HS. Global assessment of the anti-microbial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: Report from the SENTRY antimicrobial surveillance programme 2001-04. Clin Microbiol Infect 2006; 12: 315-21.
90. Conte JE, Jr, Golden JA, Kelly MG et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005; 25: 523-9.
91. Muralidharan G, Micalizzi M, Speth J et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49: 220-9.
92. Jones RN, Ferraro MJ, Reller LB et al. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol 2007; 45: 227-30.
93. Thamlikitkul V, Trakulsomboon S. In vitro activity of tigecycline against Burkholderia pseudomallei and Burkholderia thailandensis. Antimicrob Agents Chemother 2006; 50: 1555-7.
94. Curcio D, Fernandez F, Jones RN et al. Tigecycline disk diffusion breakpoints of Acinetobacter spp.: A clinical point of view. J Clin Microbiol 2007; 45: 2095-6.
95. Wyeth to File for FDA Approval of Tygacil for the Treatment of Patients with Community-Acquired Pneumonia. Wyeth Press Releases. http://www.wyeth.com/news?nav=display&navTo=/wyeth_html/home/news/ pressreleases/2007/1184074360162.html (12 December 2007, date last accessed).
96. Vouillamoz J, Moreillon P, Giddey M et al. In vitro activities of tigecycline combined with other antimicrobials against multiresistant Gram-positive and Gram-negative pathogens. J Antimicrob Chemother 2008; 61: 371-4.